MedTrace Logo

Metabonomics of COPD and Transplanting of Faecal Bacteria in the Treatment of Its Malnutrition

NCT04861649 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-04-27

No results posted yet for this study

Summary

Oxidative stress can affect the balance of intestinal flora and intestinal structure of patients, resulting in intestinal flora disorder. Its bacterial metabolites stimulate the parasympathetic nerve, regulate insulin secretion and other metabolic pathways of patients through neuroendocrine regulation, resulting in abnormal energy metabolism of lipids and sugars in the digestive tract, and finally lead to malnutrition.We hypothesized that fecal bacteria transplantation could reconstruct the normal intestinal flora, restore the intestinal digestion and absorption function of chronic obstructive pulmonary disease（COPD）patients and improve the state of malnutrition.

Conditions

  • Fecal Microbiota Transplantation

Interventions

BIOLOGICAL

fecal microbiota transplantation

The nasointestinal tube was placed and the fecal bacteria of healthy people were transplanted with liquid fecal bacteria (three transplants per course of treatment). 200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)

Sponsors & Collaborators

  • The First Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • Shanghai Asclepius Meditec Inc.

    lead INDUSTRY

Principal Investigators

  • Zeguang Zheng · The First Affiliated Hospital of Guangzhou Medical University

  • Yimeng Xv · The First Affiliated Hospital of Guangzhou Medical University

  • Peiyan Zhong · The First Affiliated Hospital of Guangzhou Medical University

  • Ni Liu · The First Affiliated Hospital of Guangzhou Medical University

  • Shixian Ye · The First Affiliated Hospital of Guangzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-09
Primary Completion
2023-06-30
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04861649 on ClinicalTrials.gov